FVB/N female mice were ovariectomized at week 9 and treated with saline or 0.3 mg/kg Bzb for 6 weeks (18 doses) starting at week 11.5. (A) Representative micro-CT analysis of cross sections of trabecular bone are shown for mock-treated, ovariectomized, and ovariectomized/Bzb-treated mice. Scale bar: 1.0 mm. (B) Baseline distal femur BMD increased upon Bzb treatment in both mock-treated and ovariectomized mice. *P = 0.006; **P = 0.03; n = 10 femurs/group. Quantitative analysis by micro-CT scanning revealed that ovariectomized animals had decreases in trabecular bone volume fraction and that Bzb treatment partly rescued this decrease. ^‡P = 0.001; ^†P = 0.01; n = 10 femurs/group. Trabecular number/mm decreased with ovariectomy but was rescued by Bzb treatment. ^ζP = 0.01; ^ΧP = 0.002; n = 10 femurs/group. (C) BFR per BSpm (BFR/B pm) was increased in ovary-intact animals by Bzb treatment (^#P = 0.007; n = 7 femurs) and also increased in ovariectomized animals (^††P = 0.05; n = 7 femurs). (D) Mineral apposition rate was increased in ovary-intact animals (^‡‡P = 0.01; n = 7 femurs) with Bzb treatment. In ovariectomized animals, there was increased mineral apposition, but the effect was not significant. P = 0.1.